Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors in the contemporary era, representing a significant global health concern. Early HCC patients have mild symptoms or are asymptomatic, which promotes the onset and progression of the disease. Moreover, advanced HCC is insensitive to chemotherapy, making traditional clinical treatment unable to block cancer development. Sorafenib (SFB) is a first-line targeted drug for advanced HCC patients with anti-angiogenesis and anti-tumor cell proliferation effects. However, the efficacy of SFB is constrained by its off-target distribution, rapid metabolism, and multi-drug resistance. In recent years, nanoparticles based on a variety of materials have been demonstrated to enhance the targeting and therapeutic efficacy of SFB against HCC. Concurrently, the advent of joint drug delivery systems has furnished crucial empirical evidence for reversing SFB resistance. This review will summarize the application of nanotechnology in the field of HCC treatment over the past five years. It will focus on the research progress of SFB delivery systems combined with multiple therapeutic modalities in HCC treatment. • Nanotechnology has been widely used in the treatment of hepatocellular carcinoma. • Combination therapy is an effective treatment for hepatocellular carcinoma. • Combination therapy can minimize cancer resistance to sorafenib. • A comprehensive overview of the latest delivery systems is clinically beneficial. • The nano-system can significantly improve the application defects of sorafenib.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: